This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masters, G. A. Articles by Johnson, D. Search for Related Content PubMed PubMed Citation Articles by Masters, G. A. Articles by Johnson, D. Social Bookmarking                            What's this?

Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597

From Evanston Northwestern Healthcare, Evanston, IL.

Address reprint requests to Gregory A. Masters, MD, Helen Graham Cancer Center, 4701 Ogletown-Stanton Rd, Ste 2200, Newark, DE 19713; email: gmasters{at}cbg.org.

Purpose: Gemcitabine has shown a broad range of activity in solid tumors, including previously untreated small-cell lung cancer (SCLC). The objective of this phase II trial was to investigate the activity of gemcitabine in patients with relapsed SCLC.

Patients and Methods: SCLC patients with measurable disease who had experienced treatment failure with one prior chemotherapy regimen were considered eligible. Patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and adequate organ function; signed informed consent was also required. Treatment consisted of gemcitabine 1,000 mg/m² on days 1, 8, and 15 of a 28-day cycle. Patients were stratified according to their previous response to first-line chemotherapy (primary refractory v primary sensitive disease).

Results: Forty-six patients were enrolled onto this phase II trial (20 refractory and 26 sensitive patients). Forty-two of these patients were assessable for response and survival, and 44 were assessable for toxicity. Median patient age was 60 years, and median ECOG performance status was 1. Principal grade 3/4 hematologic toxicities included neutropenia (27%) and thrombocytopenia (27%). The main grade 3/4 nonhematologic toxicities were pulmonary (9%) and neurologic toxicity (14%). Objective responses occurred in 11.9% of patients overall, including one patient with refractory SCLC (5.6%) and four patients with sensitive SCLC (16.7%). Median survival for the overall group was 7.1 months. Survival was not significantly different for patients with refractory versus sensitive disease.

Conclusion: Gemcitabine has modest activity in previously treated SCLC patients. The favorable toxicity profile warrants further investigation, either in combination chemotherapy regimens or with targeted biologic compounds.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. R. Eckardt, D. L. Bentsion, O. N. Lipatov, I. S. Polyakov, F. R. MacKintosh, D. A. Karlin, G. S. Baker, and H. B. Breitz Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer J. Clin. Oncol., April 20, 2009; 27(12): 2046 - 2051. [Abstract] [Full Text] [PDF]

				S M Lee, L E James, W Qian, S Spiro, T Eisen, N H Gower, D R Ferry, D Gilligan, P G Harper, J Prendiville, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer Thorax, January 1, 2009; 64(1): 75 - 80. [Abstract] [Full Text] [PDF]

				A. Inoue, S. Sugawara, K. Yamazaki, M. Maemondo, T. Suzuki, K. Gomi, S. Takanashi, C. Inoue, M. Inage, H. Yokouchi, et al. Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402 J. Clin. Oncol., November 20, 2008; 26(33): 5401 - 5406. [Abstract] [Full Text] [PDF]

				C. Rocha-Lima, J. Herndon II, M. Lee, J. Atkins, A Mauer, E Vokes, M. Green, and For the Cancer and Leukemia Group B Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902 Ann. Onc., February 1, 2007; 18(2): 331 - 337. [Abstract] [Full Text] [PDF]

				N. Hanna, P. A. Bunn Jr, C. Langer, L. Einhorn, T. Guthrie Jr, T. Beck, R. Ansari, P. Ellis, M. Byrne, M. Morrison, et al. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2006; 24(13): 2038 - 2043. [Abstract] [Full Text] [PDF]

				S. J. Antonia, N. Mirza, I. Fricke, A. Chiappori, P. Thompson, N. Williams, G. Bepler, G. Simon, W. Janssen, J.-H. Lee, et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer Clin. Cancer Res., February 1, 2006; 12(3): 878 - 887. [Abstract] [Full Text] [PDF]